DLDouglas Teixeira Leffa

Douglas Teixeira Leffa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas Teixeira Leffa has a total of 301 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection of tau spatial extent using MK6240 and flortaucipir PET

    by Guilherme Povala, Bruna Bellaver, Livia Amaral, Firoza Z. Lussier, Arthur C. Macedo, Pamela C.L. Ferreira, Douglas T. Leffa, Guilherme Bauer-Negrini, Marina Scop Medeiros, Emma Ruppert, et al.

    INTRODUCTION: Tau PET enables in vivo quantification of neurofibrillary tangle spread, yet whether tau spatial extent (TSE) performs comparably across tracers remains unknown. METHODS: We performed a head-to-head comparison of Flortaucipir and MK6240 tau PET in 682 individuals across the AD continuum, quantifying TSE as the percentage of regional voxels exceeding a tracer-specific abnormality threshold and evaluated it as a metric of tracer comparability. RESULTS: MK6240 showed greater TSE than Flortaucipir (CU Aβ+, medial temporal lobe [MTL]: 42% vs 25%; dementia Aβ+, late neocortical: 55% vs 42%), reaching 50% detection probability at lower Aβ burden (Centiloid: MTL, 26 vs 45; late neocortical, 95 vs 118). TSE showed higher associations than SUVR with memory, Aβ PET, and plasma pTau217, particularly in the neo-late composite. Participants with intermediate tau involvement (TSE 25–50%), most below the SUVR positivity thresholds (MTL positivity 10.2–16.9%), had approximately three-fold higher odds of Aβ PET and pTau217 positivity than TSE 0–25% (ORs 2.90–3.46). 53.4% of intermediate Flortaucipir cases (TSE 25–50%) shifted to a higher MK6240 category, and 82.5% of moderately high Flortaucipir cases (50–75%) were classified as near-saturated (75–100%) by MK6240. Neither raw TSE nor raw SUVR was directly interchangeable across tracers, with systematic and proportional bias for both metrics (MTL Deming slope: TSE 1.29; SUVR 2.69). DISCUSSION: TSE showed stronger unadjusted associations than SUVR in selected region- and outcome-specific comparisons, supporting its potential as a complementary measure. Like SUVR, raw TSE values were not directly interchangeable between flortaucipir and MK6240, and tracer-specific calibration and validation are required before cross-tracer use.

  • Open Access

    Attention‐deficit/hyperactivity disorder polygenic risk score and incidence of cognitive impairment in older adults: A prospective multicohort study

    by Douglas Teixeira Leffa, Guilherme Bauer‐Negrini, Livia Amaral, Bruna Bellaver, Pamela C. L. Ferreira, Guilherme Povala, Firoza Z. Lussier, João Pedro Ferrari‐Souza, Ann D. Cohen, Dana L. Tudorascu, et al.

    INTRODUCTION: Preliminary evidence suggests a link between attention‐deficit/hyperactivity disorder (ADHD) and later‐life cognitive impairment. Whether genetic risk for ADHD, estimated using an ADHD polygenic risk score (ADHD‐PRS), is associated with incident cognitive impairment (mild cognitive impairment or Alzheimer's disease dementia) remains unknown. METHODS: We analyzed 7761 cognitively unimpaired (CU) older adults with whole‐genome sequencing from eight cohorts participating in the Alzheimer's Disease Sequencing Project (ADSP). RESULTS: During follow‐up, 1347 participants developed cognitive impairment. Ten‐year cumulative incidence was 33.8% in the highest ADHD‐PRS tertile versus 23.4% in the lowest. In Cox models, higher ADHD‐PRS remained associated with greater risk of cognitive impairment after adjustment for education, apolipoprotein E ( APOE) ε4 status, or vascular risk. PRSs for other major psychiatric disorders were not associated with cognitive impairment in the same analytic framework. In a subsample with biomarker data, the association was not modified by baseline amyloid‐β status. DISCUSSION: These findings support ADHD‐PRS as a novel correlate of cognitive impairment and vulnerability in aging.

  • Top Cited Papers
    Open Access

    Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

    by Pamela C.L. Ferreira, Bruna Bellaver, Guilherme Povala, Guilherme Bauer-Negrini, Cristiano Schaffer Aguzzoli, João Pedro Ferrari-Souza, Douglas T. Leffa, Carolina Soares, Firoza Z. Lussier, Marina Scop Medeiros, et al.

    Plasma phosphorylated tau 217 (p-tau217) levels have been shown to parallel neurofibrillary tangle and cognitive decline over time. Although recent clinical trials have demonstrated exploratory drug effects on plasma p-tau217, little is known about plasma p-tau217 effect size and performance as an endpoint in Alzheimer disease (AD) clinical trials. Therefore, the objective of this study was to assess the longitudinal performance and potential utility of plasma p-tau217 as a primary endpoint in early-stage AD clinical trials. This retrospective study included participants from 4 cohorts: ADNI (a multisite observational study), BICWALZS (a South Korean memory clinic-based cohort), MYHAT-NI (a Southwestern Pennsylvania population-based cohort), and WRAP (older adults at risk for AD). Eligible participants had plasma p-tau217 measurements at least at 2 timepoints, along with baseline Aβ PET imaging and clinical assessments. Linear mixed-effects models were used to assess associations between plasma p-tau217 trajectories and clinical or biomarker outcomes. Effect size was defined as the mean annual rate of change in p-tau217 divided by its standard deviation. We calculated the sample size required for a hypothetical clinical trial designed to detect a 25% drug effect with 80% power at a 0.05 test level. A total of 716 individuals were included in the analysis: 413 cognitively unimpaired (CU) participants (58.6% female; mean age = 70.6 years, SD = 7.9) and 303 cognitively impaired (CI) participants (54.7% female; mean age = 73.2 years, SD = 7.4). In Aβ-positive individuals, the annual rate of change in plasma p-tau217 was similar between CU (0.07 pg/mL/y, SD = 0.11) and CI (0.08 pg/mL/y, SD = 0.13) groups. Effect size was 0.64 and 0.62 in CU and CI Aβ-positive individuals, respectively. The minimum sample size required per study group to detect a 25% drug effect was 610 for the CU Aβ-positive and 664 for the CI Aβ-positive group. Notably, selecting individuals with intermediate Aβ levels (Centiloid 20-40) yielded higher effect sizes (CU: 0.85; CI: 0.72), which reduced the required sample sizes per study group to 342 for CU and 492 for CI. Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.


  • Open Access

    Effects of in vivo Lewy body pathology on neuropsychiatric symptoms across the Alzheimer's disease continuum

    by Douglas Teixeira Leffa, Guilherme Povala, Pamela C.L. Ferreira, João Pedro Ferrari‐Souza, Guilherme Bauer‐Negrini, Matheus Scarpatto Rodrigues, Livia Amaral, Firoza Z Lussier, Marina Scop Medeiros, Carolina Soares, et al.

    Background: In Alzheimer's disease (AD) dementia, co‐pathology is frequently observed, with Lewy body (LB) pathology among the most common findings. Post‐mortem studies support a higher frequency of neuropsychiatric symptoms in individuals with AD and LB co‐pathology. To date, however, the effects of LB pathology measured in vivo on neuropsychiatric symptoms in AD is underexplored. Here, we evaluated the cross‐sectional and longitudinal effects of in vivo measured LB pathology on neuropsychiatric symptoms across the AD continuum. Method: We analyzed data from a total of 1,169 individuals from ADNI (426 cognitively unimpaired and 743 cognitively impaired; 47.13% women; mean age of 73.05 years). All participants had baseline in vivo LB pathology measured through CSF alpha‐synuclein seed amplification assays, as well as neuropsychiatric assessments using the NPI‐Q for up to 10 years. A subgroup of 977 participants had baseline CSF amyloid‐β (Aβ 1‐42 ) and p ‐tau 181 levels. We explored cross‐sectional and longitudinal effects of LB on neuropsychiatric symptoms using logistic regression and Cox proportional hazard regression models, respectively. Analyses were controlled for age, sex, and cognitive status. We further evaluated the independent effects of LB, Aβ and tau by including all three pathologies in the same model. Result: In cross‐sectional analyses at baseline, the presence of LB pathology was associated with higher rates of anxiety (OR=1.61, 95% CI=1.13‐2.29, p ‐value=0.008), apathy (OR=1.66, 95% CI=1.17‐2.36, p ‐value=0.008), motor disturbances (OR=1.96, 95% CI=1.18‐3.24, p ‐value=0.008), and appetite disturbances (OR=1.63, 95% CI=1.11‐2.40, p ‐value=0.01) after correcting for multiple comparisons (Figure 1). In longitudinal analyses, the presence of LB pathology was associated with a higher risk of developing psychosis (HR=2.15, 95% CI=1.30‐3.56, p ‐value=0.003) and anxiety (HR=1.70, 95% CI=1.22‐2.36, p ‐value=0.001, Figure 2). The cross‐sectional and longitudinal effects of LB were independent of Aβ or tau. Conclusion: Our results suggest that in vivo‐measured LB pathology is associated with a higher frequency of neuropsychiatric symptoms, with apathy, motor disturbances, appetite changes, anxiety, and psychosis as potential early neuropsychiatric manifestations of LB pathology in individuals across the AD continuum. These findings underscore the potential of in vivo LB detection as a marker for identifying individuals at elevated risk of neuropsychiatric symptoms, both in clinical trials and in clinical practice.

  • In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer’s disease continuum

    by Douglas Teixeira Leffa, Guilherme Povala, Pamela C. L. Ferreira, João Pedro Ferrari-Souza, Guilherme Bauer-Negrini, Matheus Scarpatto Rodrigues, Livia Amaral, Firoza Z. Lussier, Marina Scop Medeiros, Carolina Soares, et al.

    Intracellular alpha-synuclein aggregates, known as Lewy bodies (LB), are commonly observed in Alzheimer’s disease (AD) dementia. Post-mortem studies have shown a higher frequency of neuropsychiatric symptoms among individuals with AD and LB co-pathology. However, the effects of in vivo-measured LB pathology on neuropsychiatric symptoms in AD remain underexplored. This study aimed to evaluate cross-sectional and longitudinal effects of in vivo-measured LB pathology on neuropsychiatric symptoms across the AD continuum. We analyzed data from 1169 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Participants had in vivo measures of LB pathology (assessed using an alpha-synuclein seed amplification assay), amyloid-beta (Aβ) and phosphorylated tau (p-tau) levels in cerebrospinal fluid, and neuropsychiatric symptoms evaluated using the Neuropsychiatric Inventory-Questionnaire (NPI-Q). Logistic and Cox proportional hazards regression models were used to assess cross-sectional and longitudinal effects, respectively, adjusting for age, sex, and cognitive status. Participants had a mean baseline age of 73.05 (SD 7.22) years, 47.13% were women, 426 (36.44%) cognitively unimpaired, and 743 (63.56%) cognitively impaired. In cross-sectional analyses, LB pathology was associated with higher rates of anxiety, apathy, motor disturbances, and appetite disturbances. In longitudinal analyses, LB pathology increased the risk of developing psychosis and anxiety. These effects were independent of Aβ and p-tau. Our results suggest that in vivo-measured LB pathology is closely associated with neuropsychiatric symptoms across the AD continuum. These findings underscore the potential of in vivo LB detection as a marker for identifying individuals at increased risk of neuropsychiatric symptoms, both in clinical trials and in clinical practice.


  • Open Access

    Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease

    by João Pedro Ferrari-Souza, Guilherme Povala, Nesrine Rahmouni, Bruna Bellaver, Pamela C. L. Ferreira, Marco Antônio De Bastiani, Douglas T. Leffa, Firoza Z. Lussier, Cristiano S. Aguzzoli, Wagner S. Brum, et al.

    Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer’s disease (AD). In this study, we investigated the association between microglial activation and amyloid-β (Aβ) with reactive astrogliosis in individuals across the AD spectrum. We examined 101 individuals using positron emission tomography radiotracers to assess Aβ deposition ([18F]AZD4694), tau aggregation ([18F]MK-6240) and microglial activation ([11C]PBR28), along with plasma biomarkers for astrocyte reactivity (GFAP) and tau phosphorylation (p-tau217). We further evaluated 251 individuals with cerebrospinal fluid levels of the microglial marker sTREM2. We found that Aβ pathology was associated with astrocyte reactivity across cortical brain regions only in the presence of microglial activation. The microglia-dependent effects of Aβ on astrocyte reactivity were further related to cognitive impairment through tau phosphorylation and aggregation. Our results suggest that microglial activation plays a key role in Aβ-related astrocyte reactivity, which, in turn, contributes to downstream pathological features of AD.


  • Open Access

    Association Between the Genetic Risk for Attention-Deficit/Hyperactivity Disorder and Cognitive Function in Older Age: The MYHAT Population-Based Study

    by Douglas Teixeira Leffa, Yingjin Zhang, Yueting Wang, Esther G. Teverovsky, Erin Jacobsen, Bruna Bellaver, Pamela C.L. Ferreira, Kang-Hsien Fan, M. Ilyas Kamboh, Thomas K. Karikari, et al.


  • Open Access

    CSF total tau as a proxy of synaptic degeneration

    by Carolina Soares, Bruna Bellaver, Pamela C. L. Ferreira, Guilherme Povala, Cristiano Schaffer Aguzzoli, João Pedro Ferrari-Souza, Hussein Zalzale, Firoza Z. Lussier, Francieli Rohden, Sarah Abbas, et al.

    Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts. We observe a stronger correlation between CSF t-tau and synaptic biomarkers than neurodegeneration biomarkers in both groups. Synaptic biomarkers explain a greater proportion of variance in CSF t-tau levels compared to neurodegeneration biomarkers. Notably, CSF t-tau levels are elevated in individuals with abnormalities only in synaptic biomarkers, but not in individuals with abnormalities only in neurodegeneration biomarkers. Our findings suggest that CSF t-tau is a closer proxy for synaptic degeneration than for axonal/neuronal degeneration.


  • Enhancing Goal Achievement in Adults With ADHD: A Participant-Centered Evaluation of Transcranial Direct Current Stimulation From the TUNED Trial

    by Maitê Schneider, Carolina Prietto Ferrazza, Roberta Francieli da Silva Bomber, Felipe Picon, Diego Luiz Rovaris, Paulo Roberto Stefani Sanches, Danton Pereira, André Russowsky Brunoni, Joan A. Camprodon, Wolnei Caumo, et al.

    Objective: Few trials in ADHD incorporate participant-centered outcomes that evaluate the impact of interventions on meaningful life activities. Additionally, in psychiatry, the translation of changes in symptom rating scales into meaningful impacts on participants’ lives has been questioned. The Transcranial Direct Current Stimulation (tDCS) for the Treatment of Inattention Symptoms in Adult Patients with ADHD (TUNED) trial demonstrated improved inattention symptoms, assessed using a clinician-administrated scale, after a 4-week treatment with daily home-based tDCS in adults with ADHD. Here, our primary objective was to evaluate the impact of tDCS in ADHD using a participant-centered and clinically relevant outcome. Method: We analyzed data from the TUNED trial (ClinicalTrials.gov Identifier: NCT04003740), a randomized, double-blind, parallel, sham-controlled study testing tDCS in adults with ADHD. At the baseline assessment, all participants were instructed to select up to three goals they desired to achieve during the trial period. The goals had to be specific, measurable, achievable, relevant, and time-bound. Our main outcome was the number of goals achieved at the end of the intervention. Results: Of the 64 participants randomized, 55 completed the trial and were included in the analyses (26 [47%] inattentive presentation and 29 [53%] combined presentation; mean ( SD ) age, 38.1 [9.8] years; 40% women). In the active tDCS group ( n = 25), eight participants (32%) achieved one goal, 5 (20%) achieved two goals, 3 (12%) achieved all three goals, and 9 (36%) achieved no goals. In the sham tDCS group ( n = 30), 3 (10%) participants achieved one goal, 3 (10%) achieved two goals, 3 (10%) achieved all three goals, and 21 (70%) achieved no goals. Ordinal logistic regression analyses showed that participants in the active tDCS group were more likely to achieve a higher number of goals compared to those in the tDCS sham group (OR = 3.05, 95% CI [1.06, 8.75], p = .03]). Conclusion: This study demonstrated that tDCS can significantly enhance the ability to achieve personal goals in adults with ADHD. By using a participant-centered approach, our findings not only support tDCS as a promising treatment for ADHD but also align with the growing emphasis on personalized medicine and clinically relevant, participant-reported outcomes in clinical research.